Supernus Pharmaceuticals Hits New 52-Week High of $47.07

Supernus Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 47.07 on September 22, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 2.57 billion.
Over the past year, Supernus Pharmaceuticals has demonstrated impressive growth, with a remarkable 79.38% increase in stock price, significantly outperforming the S&P 500, which recorded a 16.64% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 29.00, reflecting its valuation in the market. Additionally, Supernus maintains a debt-to-equity ratio of -0.48, indicating a solid financial position.

Despite not offering dividends, the company showcases a return on equity of 6.51% and a price-to-book ratio of 2.42. The stock's previous 52-week low was recorded at USD 29.16, highlighting the substantial upward movement in its price. This performance positions Supernus Pharmaceuticals as a noteworthy player in its industry.